Every season plays out differently, but once summer fades, people start to think about flu season and when to get their shots. This year is no different. If anything, without pandemic restrictions and the roll-out of new COVID-19 booster shots, it’s expected to be busier than normal.

The U.K. became the first county to pass a modified COVID-19 vaccine, which targets the Omicron variant. Other countries, including Canada and Australia, are expected to follow suit.1 In the U.S., the Food and Drug Administration (FDA) authorized COVID-19 booster shots that target the Omicron BA.5 subvariant as the country prepares for another expected surge of infections this fall and winter.

It marks the first time the FDA has authorized an updated vaccine since the original shots became available in December 2020. The U.S. has, so far, secured 171 million doses of Moderna’s and Pfizer’s updated vaccines.2

Moderna and Pfizer have peacefully dominated the COVID-19 vaccine market, but that truce has come to an end. Moderna recently filed a patent infringement lawsuit against Pfizer and its partner BioNTech in the U.S. and Germany for patents Moderna says it filed between 2010 and 2016.3

Moderna is looking to protect the innovative mRNA technology it pioneered and patented in the decade leading up to the pandemic, allowing it to develop its own COVID-19 vaccine, Spikevax, in “record time.”

Roche Holdings Ltd

Roche Holdings Ltd. recently launched its Digital LightCycler Systems, a digital polymerase chain reaction system that helps clinical researchers better understand the nature of a patient’s cancer, infection, or genetic disease and lead to early diagnosis and treatment strategies.

The Digital LightCycler Systems will be available in 15 countries in 2022, with plans to launch in additional countries in the near future.4

Roche also announced the launch of the Elecsys IGRA SARS-CoV-2, a new diagnostic test designed to better understand the immune response to SARS-CoV-2 infection or vaccination.5

Siemens AG

Siemens AG is a special industrial machinery giant whose Siemens Healthineers segment develops, manufactures, and sells various diagnostic and therapeutic products and services. It also provides clinical consulting services.

The Munich, Germany-based company announced recently that its Deep Resolve Magnetic Resonance Imaging (MRI) system, powered by Artificial Intelligence (AI), allows users to accelerate MRI scans by up to 70%.6

The quality of MRI imaging is defined by the trade-off between scan time, image noise, and resolutions. Improving one means compromising on the others. Deep Resolve eliminates this dilemma, enabling clinicians to choose a faster scan time while reducing noise and keeping the same resolution.

For example, traditional MRI imaging on the knee can take approximately 10 minutes, but with Deep Resolve, the time has been reduced to under two minutes. Deep Resolve is not limited to a particular region of the body and can be used in almost every diagnostic procedure using MRI.

Investing in Healthcare with LIFE ETF

The Evolve Global Healthcare Enhanced Yield Fund (LIFE ETF) provides investors with exposure to twenty global blue-chip healthcare companies with a covered call strategy that is actively managed to provide increased yield potential while helping mitigate risk. The LIFE ETF is available in hedged, unhedged and USD classes.

Managed by an established team of industry veterans with a proven track record of success, Evolve ETFs creates investment products that make a difference. For more information, please visit www.evolveetfs.com or download our one-pager about LIFE ETF.


For the month, Roche Holdings Ltd made the largest contribution to the Fund. The largest detractors to performance for the month were GSK PLC, followed by Sanofi ADR, and Zoetis Inc. On last rebalance, these securities were added to the portfolio: Siemens AG and Zoetis Inc. By weight, the Fund’s largest geographic exposure was to the United States, followed by Switzerland and Britain.

To stay updated with insights on investing and industry updates on related investment products, sign up for our weekly newsletter here.



  1. Loftus, P., “Variant-Targeted Covid-19 Boosters Test the Promise of mRNA Technology,” The Wall Street Journal, August 21, 2022; https://www.wsj.com/articles/variant-targeted-covid-19-boosters-test-the-promise-of-mrna-technology-11661030696.
  2. Kimball, S., “FDA authorizes Covid booster shots that target omicron BA.5 variant,” CNBC, August 31, 2022; https://www.cnbc.com/2022/08/31/fda-authorizes-covid-booster-shots-that-target-omicron-bapoint5-variant-.html?__source=iosappshare%7Ccom.microsoft.Office.Outlook.compose-shareextension.
  3. “Moderna Sues Pfizer And BioNTech For Infringing Patents Central To Moderna’s Innovative MRNA Technology Platform,” Moderna, Inc., August 26, 2022; https://investors.modernatx.com/news/news-details/2022/Moderna-Sues-Pfizer-and-BioNTech-for-Infringing-Patents-Central-to-Modernas-Innovative-mRNA-Technology-Platform/default.aspx.
  4. “Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases,” Roche, August 22, 2022; https://www.roche.com/media/releases/med-cor-2022-08-23.
  5. “Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2,” Roche, August 14, 2022; https://www.roche.com/media/releases/med-cor-2022-08-15.
  6. “Siemens Healthineers accelerates and improves Magnetic Resonance Imaging with Artificial Intelligence,” Siemens Healthineers, July 13, 2022; https://www.siemens-healthineers.com/press/releases/deepresolve.


The contents of this blog are not to be used or construed as investment advice or as an endorsement or recommendation of any entity or security discussed. These contents are not an offer or solicitation of an offer or a recommendation to buy or sell any securities or financial instrument, nor shall it be deemed to provide investment, tax or accounting advice. The information contained herein is intended for informational purposes only.
Commissions, management fees and expenses all may be associated with exchange traded funds (ETFs) and mutual funds (funds). Please read the prospectus before investing. ETFs and mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated. There are risks involved with investing in ETFs and mutual funds. Please read the prospectus for a complete description of risks relevant to ETFs and mutual funds. Investors may incur customary brokerage commissions in buying or selling ETF and mutual fund units.
Certain statements contained in this blog may constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to a future outlook and anticipated distributions, events or results and may include statements regarding future financial performance. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “anticipate”, “believe”, “intend” or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Evolve Funds undertakes no obligation to update publicly or otherwise revise any forward-looking statement whether as a result of new information, future events or other such factors which affect this information, except as required by law.

Tags COVID-19  ETF Investing  Evolve Global Healthcare Enhanced Yield Fund  global healthcare  healthcare etf  investing  LIFE ETF  Moderna  Pandemic  pfizer  Siemens  vaccine